Kenvue Earnings Call Transcripts
Fiscal Year 2026
-
The meeting confirmed a quorum and proceeded with the election of 12 directors, approval of executive compensation, and ratification of the auditor. All proposals passed, with final results to be filed in a Form 8-K.
-
Stockholders were presented with and approved proposals for a merger, related compensation, and adjournment (the latter not called due to merger approval). The board unanimously supported all proposals, and final results will be filed with the SEC.
Fiscal Year 2025
-
The merger creates a global health and wellness leader with $32B in revenue, $7B in EBITDA, and 10 iconic brands. Expected synergies of $2.1B in EBITDA will be realized within four years, with a focus on innovation, operational discipline, and portfolio optimization. The deal is valued at $48.7B and targets closing in H2 2026.
-
Q2 organic sales declined 4.2% year-over-year, with margin contraction and EPS below last year. Leadership is focused on simplifying operations, improving execution, and reviewing strategic alternatives, while 2025 guidance was revised downward amid ongoing macro and category headwinds.
-
After completing a major separation and transformation, the company is focused on profitable growth through increased brand investment, operational efficiencies, and a robust innovation pipeline. Despite near-term headwinds from pricing, destocking, and macro pressures, the outlook for the second half is positive, with strong marketing and product launches expected to drive acceleration.
-
The meeting covered board elections, approval of executive compensation, and auditor ratification. Financial highlights included 1.5% organic sales growth and a 200 basis point margin increase. Strategic priorities for 2025 focus on brand growth, operational efficiency, and innovation.
-
Q1 organic sales declined 1.2% year-over-year, with strong execution offset by macro and seasonal headwinds. 2025 guidance maintains 2%-4% organic sales growth, but adjusted EPS is now expected to be flat due to $150M in tariffs and FX. Brand investments and innovation are set to drive back-half acceleration.
-
The event detailed a strategic transformation toward profitable growth, highlighting operational independence, a new five-pillar brand framework, and accelerated innovation. Financial guidance for 2025 includes 2%-4% organic sales growth, margin expansion, and increased free cash flow.
Fiscal Year 2024
-
Organic sales grew 1.5% in 2024, below expectations due to weak cold/flu season and Asia-Pacific distributor issues, but gross margin expanded and brand investment rose 20%. 2025 guidance targets 2%-4% organic sales growth, with recovery expected in H2 as headwinds subside.
-
Eighteen months post-separation, the company has made strong operational and financial progress, with significant cost savings, margin expansion, and increased investment in brand activation. Growth is driven by underpenetrated categories, innovation, and disciplined capital allocation.
-
Q3 saw 0.9% organic growth, strong margin expansion, and continued investment in brands despite softer top-line trends. Full-year organic growth is expected at the low end of guidance, with productivity gains offsetting category headwinds.
-
The company is progressing on its transformation to a standalone, growth-focused entity, with operational efficiencies funding increased brand investment and innovation. Strong engagement, influencer-led marketing, and targeted strategies in skin health and beauty are expected to drive growth, with full-year guidance reaffirmed and disciplined capital allocation supporting long-term TSR.
-
Q2 delivered 1.5% organic growth and a 410 bps rise in adjusted gross margin, with strong Essential Health performance and sequential improvement in Skin Health and Beauty. Brand investment increased 20% year-over-year, and full-year guidance remains unchanged.
-
The organization is executing a transformation focused on accelerated growth, operational efficiency, and a performance-driven culture. Self-care and essential health segments are strong, while U.S. skin health is under recovery. Financially, gross margins are robust, with investments prioritized for brand growth and innovation, and M&A is deprioritized until transformation goals are met.